A U Buzdar

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer
    Aman Buzdar
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:3244-53. 2012
  2. ncbi Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer
    A U Buzdar
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Ann Oncol 23:589-97. 2012
  3. ncbi Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer
    Catherine M Kelly
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 30:930-5. 2012
  4. ncbi CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
  5. ncbi Aromatase inhibitors: changing the face of endocrine therapy for breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Breast Dis 24:107-17. 2005
  6. ncbi Medical oncology: Endocrine-therapy-related symptoms and breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 6:309-10. 2009
  7. ncbi Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer
    Aman U Buzdar
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 8:335-41. 2003
  8. ncbi Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial
    Aman Buzdar
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Breast Cancer 4:S42-8. 2003
  9. ncbi Aromatase inhibitors alone or in sequence with tamoxifen - Clinical Evaluation of the BIG 1-98 trial
    Catherine M Kelly
    The University of Texas M D Anderson Cancer Center, Department of Breast Medical Oncology, Unit 1354, PO Box 301439, Houston, TX 77230 1439, USA 1 713 792 7462 1 713 794 4385
    Expert Opin Pharmacother 11:489-92. 2010
  10. ncbi How rapidly do oncologists respond to clinical trial data?
    Aman Buzdar
    Department of Medical Oncology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 10:15-21. 2005

Collaborators

Detail Information

Publications110 found, 100 shown here

  1. ncbi Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer
    Aman Buzdar
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:3244-53. 2012
    ....
  2. ncbi Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer
    A U Buzdar
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Ann Oncol 23:589-97. 2012
    ..This phase II study investigated whether a lower-than-approved dose of capecitabine, plus docetaxel (XT), would improve tolerability versus standard-dose XT without compromising efficacy...
  3. ncbi Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer
    Catherine M Kelly
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 30:930-5. 2012
    ..We investigated whether capecitabine and docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) or weekly paclitaxel (WP) followed by FEC would improve relapse-free survival (RFS) in operable breast cancer...
  4. ncbi CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
    ..We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC)...
  5. ncbi Aromatase inhibitors: changing the face of endocrine therapy for breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Breast Dis 24:107-17. 2005
    ..Ongoing trials aim to clarify the role of the AIs in preoperative treatment and chemoprevention...
  6. ncbi Medical oncology: Endocrine-therapy-related symptoms and breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 6:309-10. 2009
    ..The development of vasomotor or joint symptoms is an indication of therapeutic benefit in women receiving endocrine treatment for hormone-receptor-positive breast cancer...
  7. ncbi Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer
    Aman U Buzdar
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 8:335-41. 2003
    ..Although longer follow-up is warranted, anastrozole appears to be a well-documented choice of endocrine adjuvant therapy for postmenopausal women with hormone-responsive breast cancer...
  8. ncbi Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial
    Aman Buzdar
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Breast Cancer 4:S42-8. 2003
    ..Anastrozole is now emerging as a new standard for the adjuvant treatment of postmenopausal women with hormone-sensitive early-stage breast cancer. New adjuvant trials are currently using anastrozole in the control arm...
  9. ncbi Aromatase inhibitors alone or in sequence with tamoxifen - Clinical Evaluation of the BIG 1-98 trial
    Catherine M Kelly
    The University of Texas M D Anderson Cancer Center, Department of Breast Medical Oncology, Unit 1354, PO Box 301439, Houston, TX 77230 1439, USA 1 713 792 7462 1 713 794 4385
    Expert Opin Pharmacother 11:489-92. 2010
    ..Conclusion: This is the second large Phase III trial to show that upfront AI use is superior to tamoxifen...
  10. ncbi How rapidly do oncologists respond to clinical trial data?
    Aman Buzdar
    Department of Medical Oncology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 10:15-21. 2005
    ..This study suggests that the dissemination of key clinical data, accompanied by professional commentary and regulatory actions, can rapidly influence the clinical practice of medical oncologists...
  11. ncbi Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer
    Aman Buzdar
    M D Anderson Cancer Center and US Oncology Research, Houston, and Baylor Sammons Cancer Center and Texas Oncology, Dallas, TX 77030, USA
    J Clin Oncol 21:1007-14. 2003
    ....
  12. ncbi Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:468S-72S. 2003
    ..The effects of anastrozole, letrozole, and exemestane are being investigated in the adjuvant setting, and these data will elucidate the possible long-term consequences of the pharmacological effects reported after short-term exposure...
  13. ncbi Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen
    Aman U Buzdar
    Department of Breast Medical Oncology, Box 424, University of Texas MD Anderson Cancer Center, 1515 Holcolme Blvd, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 2:623-9. 2002
    ..0001 for both). This review focuses on both the clinical pharmacology and the clinical data of anastrozole with emphasis on its future applications...
  14. ncbi An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 95:2006-16. 2002
    ..Because these agents ultimately may be administered for periods of up to 5 years in the adjuvant setting, it is of increasing importance to assess their tolerability and pharmacologic profiles...
  15. ncbi New generation aromatase inhibitors--from the advanced to the adjuvant setting
    Aman U Buzdar
    Department of Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston 77030 4009, USA
    Breast Cancer Res Treat 75:S13-7; discussion S33-5. 2002
    ....
  16. ncbi Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer
    A Buzdar
    The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Breast Cancer Res Treat 73:161-75. 2002
    ....
  17. ncbi Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer
    Aman U Buzdar
    Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Pharmacother 40:1572-83. 2006
    ..To compare the pharmacologic profile of fulvestrant with that of tamoxifen and the aromatase inhibitors with respect to the choice of treatment for advanced breast cancer (ABC)...
  18. ncbi Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer
    A U Buzdar
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 20:993-9. 2009
    ..Design: Literature published from January 2003 to March 2008 was reviewed to assess the use of chemotherapy and biologic therapy in addition to hormonal agents...
  19. ncbi Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer
    Aman U Buzdar
    The University of Texas, M.D. Anderson Cancer Center, Houston TX, USA
    Cancer Treat Rev 29:449-52. 2003
  20. ncbi Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer
    Aman U Buzdar
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs Today (Barc) 44:679-92. 2008
    ....
  21. ncbi Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data
    Aman U Buzdar
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 12:1037s-1048s. 2006
    ..These data suggest that long-term safety profiles may differ between aromatase inhibitors, although comprehensive comparative data for letrozole and exemestane versus tamoxifen are lacking...
  22. ncbi Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:228-33. 2007
    ..All data were updated through November 2005...
  23. ncbi Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
    J Clin Oncol 23:3676-85. 2005
    ....
  24. ncbi TAS-108: a novel steroidal antiestrogen
    Aman U Buzdar
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:906s-8s. 2005
    ..In the phase I study, there was evidence of biological antitumor activity, with stable disease noted in several patients. A phase II study is ongoing, and phase III studies are being planned with the drug...
  25. ncbi Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:700-9. 2008
    ..Outstanding issues to optimize AI therapy include identifying the optimal duration, agent, and patients for these therapies...
  26. ncbi Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer
    Aman U Buzdar
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs Today (Barc) 40:751-64. 2004
    ..Therefore, fulvestrant is a versatile new treatment option for postmenopausal women with advanced breast cancer who have progressed on prior endocrine therapy...
  27. ncbi The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update
    Aman U Buzdar
    The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Clin Breast Cancer 5:S6-S12. 2004
    ..This review concludes that, based on the overall risk-benefit profile from the ATAC study, anastrozole is a rational alternative to tamoxifen for the adjuvant treatment of women with hormone-sensitive early-stage breast cancer...
  28. ncbi Current developments in hormonal therapy of breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030-4009, USA
    Clin Breast Cancer 5:S4-5. 2004
  29. ncbi The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women
    Aman U Buzdar
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Breast J 10:211-7. 2004
    ..Overall these data confirm that hormone receptor status should be a strong consideration in the selection of endocrine treatment for postmenopausal women with advanced breast cancer...
  30. ncbi Clinical experience with epothilones in patients with breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 8:S71-8. 2008
    ..Ongoing phase II/III trials continue to assess ixabepilone and other members of the epothilone family in breast cancer, particularly in combination regimens, as being valid treatment options in multidrug-resistant breast cancer...
  31. ncbi Aromatase inhibitors in breast cancer therapy
    Aman U Buzdar
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030, USA
    Clin Breast Cancer 4:S84-8. 2003
    ....
  32. ncbi Anastrozole for breast cancer: recent advances and ongoing challenges
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030 4009, USA
    Expert Rev Anticancer Ther 6:839-48. 2006
    ..Treatment recommendations and the future role of anastrozole in the management of patients with early breast cancer are also considered...
  33. ncbi 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Centre, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Steroid Biochem Mol Biol 86:399-403. 2003
    ..For the first time a choice now exists for adjuvant endocrine treatment for postmenopausal women with hormone responsive tumours. Longer follow-up will further define the benefit/risk of anastrozole adjuvant therapy...
  34. ncbi Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1073-9. 2002
    ..In this prospective randomized trial, the role of paclitaxel was evaluated in an adjuvant setting to determine its impact on reducing the risk of recurrence in patients with operable breast cancer...
  35. ncbi Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
    A U Buzdar
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:3412-7. 1999
    ..To compare prospectively the antitumor activity of single-agent paclitaxel to the three-drug combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer...
  36. ncbi A summary of second-line randomized studies of aromatase inhibitors
    A U Buzdar
    Department of Breast Medical Oncology, M D Anderson Cancer Center, M D University of Texas, Box 424, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Steroid Biochem Mol Biol 79:109-14. 2001
    ..Studies in the adjuvant setting will ultimately determine whether the differences in pharmacokinetics and phamacodynamics will be of clinical relevance...
  37. ncbi Tamoxifen's clinical applications: old and new
    A U Buzdar
    Department of Breast Medical Oncology, M D Anderson Cancer Center, Houston, TX 77037, USA
    Arch Fam Med 9:906-12. 2000
    ..Arch Fam Med. 2000;9:906-912..
  38. ncbi Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
    A Buzdar
    University of Texas M D Anderson Cancer Center and Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 19:3357-66. 2001
    ..To compare two doses of letrozole (0.5 mg and 2.5 mg every day) and megestrol acetate (40 mg qid) as endocrine therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens...
  39. ncbi Exemestane in advanced breast cancer
    A Buzdar
    University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Anticancer Drugs 11:609-16. 2000
    ..Discontinuation due to adverse events is rare. Exemestane is a safe and well-tolerated alternative for the treatment of postmenopausal patients with advanced breast cancer...
  40. ncbi Preoperative chemotherapy treatment of breast cancer--a review
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2394-407. 2007
    ..The future of neoadjuvant therapy lies in tailoring treatment to individual patients by identifying response predictors and developing novel agents. This ultimately may lead to improved outcomes for women with breast cancer...
  41. ncbi Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results
    F A Holmes
    Department of Breast Medical Oncology, University of Texas, M D Anderson Cancer Centre, Houston, USA
    Ann Oncol 10:403-11. 1999
    ..We and others have demonstrated the antineoplastic efficacy of paclitaxel as a single agent in metastatic breast cancer. We performed this phase I trial to evaluate the combination of paclitaxel with doxorubicin...
  42. ncbi Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience
    R A Brito
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:628-33. 2001
    ....
  43. ncbi Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
    F Peintinger
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Oncol 19:2020-5. 2008
    ....
  44. ncbi Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
    G N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Natl Cancer Inst 92:225-33. 2000
    ..We conducted a prospective randomized trial to compare standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy. PATIENTS and..
  45. ncbi Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy
    E Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Cancer 89:2195-201. 2000
    ..The authors conducted a single institution Phase II clinical trial to determine whether paclitaxel had antitumor activity in patients with metastatic breast carcinoma that was refractory to standard chemotherapy...
  46. ncbi Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma
    H M Kuerer
    Department of Surgical Oncology, Box 444, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Surg 182:601-8. 2001
    ..Resection of the tumor bed remains necessary in women deemed to have a complete clinical response to ensure low rates of recurrence...
  47. ncbi Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy
    T A Buchholz
    Departments of Radiation Oncology, Biomathematics, Breast Medical Oncology, and Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:2240-6. 2001
    ..To determine the impact of tamoxifen and chemotherapy on local control for breast cancer patients treated with breast-conservation therapy...
  48. ncbi Paclitaxel in the multimodality treatment for inflammatory breast carcinoma
    M Cristofanilli
    Department of Breast Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 92:1775-82. 2001
    ..Reports of significant clinical activity of paclitaxel in metastatic breast carcinoma led the authors to investigate the role of this drug in the management of IBC...
  49. ncbi Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
    C Mazouni
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Ann Oncol 18:874-80. 2007
    ....
  50. ncbi Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up
    N K Ibrahim
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 11:1597-601. 2000
    ..The purpose of this study was to evaluate the clinical outcome of doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients and to compare results in elderly patients with those in younger patients...
  51. ncbi Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
    Z U Rahman
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 15:3171-7. 1997
    ..We report the long-term results of patients with metastatic breast cancer who were eligible for HDCT but were treated with doxorubicin-containing standard-dose chemotherapy...
  52. ncbi Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer
    N K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Lancet 355:281-3. 2000
    ....
  53. ncbi Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer
    V Valero
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 17:1425-34. 1999
    ....
  54. ncbi Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases
    G Vlastos
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
    Ann Surg Oncol 8:425-31. 2001
    ..0001). CONCLUSIONS: Occult primary carcinoma with axillary metastases can be treated with preservation of the breast without a negative impact on local control or survival...
  55. ncbi Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy
    T A Buchholz
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
    Cancer J 7:413-20. 2001
    ..However, more active systemic and local therapies are needed for patients with estrogen receptor-negative disease and positive lymph nodes and for those with clinical evidence of progressive disease during neoadjuvant chemotherapy...
  56. ncbi Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma
    N K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer 91:664-71. 2001
    ....
  57. ncbi Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience
    Q Xiong
    Division of Cancer Medicine; University of Texas M. D. Anderson Cancer Center; Houston, Texas 77030, USA
    Cancer 92:2523-8. 2001
    ..CONCLUSIONS: Women who are diagnosed with breast carcinoma at an age < or = 30 years appear to have a poorer prognosis compared with that for their older counterparts...
  58. ncbi Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast
    H M Kuerer
    Department of Surgical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Surg Oncol 77:139-47. 2001
    ..These trials will answer some of the many questions that remain regarding optimal hormonal therapy for hormone-dependent breast cancer...
  59. ncbi Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer
    L A Newman
    Department of Surgical Oncology, Box 444, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Surg 181:313-8. 2001
    ....
  60. ncbi Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond
    F J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 56, Houston, TX 77030, USA
    Oncologist 6:133-46. 2001
    ..Other novel biologic therapies interfere with signal transduction pathways and angiogenesis. The challenge for the next decade will be to integrate these promising agents in the management of metastatic and primary breast cancer...
  61. ncbi Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation
    N K Ibrahim
    Division of Medicine, Department of Breast Medical Oncology, Box 56, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer Invest 19:459-66. 2001
    ..v. bolus followed by a continuous infusion of 10 mg/m2/day over 4 days. However, this treatment schedule offers no apparent advantage over the commonly used weekly vinorelbine schedule...
  62. ncbi Combination endocrine therapy in the management of breast cancer
    L B Michaud
    The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 6:538-46. 2001
    ..However, many exciting new agents are on the horizon that offer hope to further advance the progress made to date although further confounding the questions already answered...
  63. ncbi Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry
    F J Esteva
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095, USA
    Pathol Oncol Res 7:171-7. 2001
    ..Further research is needed to determine the prognostic and predictive roles of the various associations between HER receptors, their ligands and signal transduction molecules in patients with early-stage breast cancer...
  64. ncbi A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up
    Vasily Assikis
    Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Cancer 97:2716-23. 2003
    ....
  65. ncbi Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy
    A U Buzdar
    Department of Breast and Gynecology Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:348-53. 1998
    ..A new antiestrogen, toremifene, was approved recently for use in managing metastatic breast cancer in postmenopausal women...
  66. ncbi Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
    A U Buzdar
    Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston 77030, USA
    Br J Cancer 85:6-10. 2001
    ....
  67. ncbi Endocrine therapy in the treatment of metastatic breast cancer
    A U Buzdar
    Department of Breast Medical Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77037, USA
    Semin Oncol 28:291-304. 2001
    ..Results are anxiously awaited from trials of new endocrine agents including the first member of a new class of endocrine agent, the estrogen-receptor downregulator class. Semin Oncol 28:291-304...
  68. ncbi Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer
    Aman Buzdar
    University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Med Res Opin 22:1575-85. 2006
    ..However, there remain issues regarding the best way to use AIs, such as the optimal length of AI treatment and how a sequence of tamoxifen followed by an AI compares with AI monotherapy; these will require further data to resolve...
  69. ncbi Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis
    S Chang
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston 77030 4095, USA
    Breast Cancer Res Treat 64:157-63. 2000
    ....
  70. ncbi Recent advances in aromatase inhibitor therapy for breast cancer
    Vasily J Assikis
    Divisions of Cancer Medicine and Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 29:120-8. 2002
    ..We will also present the design and rationale of ongoing trials looking into the use of third-generation aromatase inhibitors in the adjuvant setting and review data regarding their possible role in premenopausal women...
  71. ncbi Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel
    Cielito C Reyes-Gibby
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Pain 10:1146-50. 2009
    ..We found CIPN as a predictor of NP. Understanding the epidemiology of NP in breast cancer patients has high clinical and public health significance...
  72. ncbi Inflammatory breast cancer and body mass index
    S Chang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    J Clin Oncol 16:3731-5. 1998
    ..Because high body mass index (BMI) is associated with decreased risk of premenopausal breast cancer but increased risk of postmenopausal breast cancer, we evaluated whether high BMI was a risk factor for IBC...
  73. ncbi Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger
    Yesim Eralp
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
    J Cancer Res Clin Oncol 135:141-8. 2009
    ..The aim of this study is to evaluate the impact of body mass index (BMI) and various prognostic factors on pathologic response and survival in young patients with localized breast cancer...
  74. ncbi A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer
    L Johnetta Blakely
    Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5425-31. 2004
    ..The drug has linear pharmacokinetics, and in this heavily treated patient population, there was evidence of biological antitumor activity. A multi-institutional phase II study is planned...
  75. ncbi Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers
    C Mazouni
    Laboratoire de transfert biologique et oncologique, Marseille University, Houston, TX, USA
    Br J Cancer 99:68-71. 2008
    ..In conclusion, patients with breast cancer have elevated levels of collagen IV compared to healthy women and collagen IV levels increase further during chemotherapy...
  76. ncbi Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease
    Julie R Gralow
    Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3 200, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:814-9. 2008
    ..To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer...
  77. ncbi Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference
    Steven E Come
    Breast Cancer Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 112:673-8. 2008
    ..All of this has and continues to contribute to a growing understanding of how to optimize the use of endocrine agents in both treating and preventing breast cancer...
  78. ncbi Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy
    Chafika Mazouni
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 109:496-501. 2007
    ....
  79. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..This test correctly identified all but one of the patients who achieved pCR (12 of 13 patients) and all but one of those who were predicted to have residual disease had residual cancer (27 of 28 patients)...
  80. ncbi Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer
    Vijayalaxmi Deshmane
    Department of Surgical Oncology, Kidwai Memorial Institute of Oncology, Karnataka, Bangalore, India
    J Clin Oncol 25:4967-73. 2007
    ..To compare the efficacy of arzoxifene with tamoxifen for the treatment of locally advanced or metastatic breast cancer...
  81. ncbi In brief
    Judy C Boughey
    Mayo Clinic, Rochester, Minnesota, USA
    Curr Probl Surg 45:6-11. 2008
  82. ncbi Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis
    Ivana Sestak
    Cancer Research UK, Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, London, UK
    Lancet Oncol 9:866-72. 2008
    ..The aim of this study was to assess the relative importance of different risk factors for treatment-emergent joint symptoms in patients assigned to anastrozole or tamoxifen as adjuvant treatment for postmenopausal breast cancer...
  83. ncbi Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1195-200. 2007
    ..The purpose of this study was to review the efficacy and safety of a similar regimen outside the setting of a clinical trial...
  84. ncbi The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy
    Florentia Peintinger
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:1248-54. 2006
    ..Prospective studies are needed to examine whether decreasing the RVs in this patient population leads to an increased LRR rate...
  85. ncbi Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
    Radhika Rajan
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Cancer 100:1365-73. 2004
    ....
  86. ncbi Hormonal therapy in early and advanced breast cancer
    Aman U Buzdar
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Breast J 10:S19-21. 2004
    ....
  87. ncbi Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence
    L Johnetta Blakely
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:465-9. 2004
    ..71 (P=0.4). CONCLUSIONS: In the current study population, pregnancy was not associated with an increased risk of disease recurrence or poorer survival in patients previously treated for breast carcinoma...
  88. ncbi Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003
    Aman U Buzdar
    The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:355S-61S. 2004
    ..Anastrozole should, therefore, now be considered a valid alternative option to tamoxifen for adjuvant hormonal treatment in all postmenopausal women with hormone receptor-positive early breast cancer...
  89. ncbi Role of anastrozole in adjuvant therapy for postmenopausal patients
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 30:21-9. 2003
    ..The results of the Arimidex, Tamoxifen, Alone or in Combination trial show anastrozole to be an effective and well tolerated endocrine option for early breast cancer and provide evidence for its potential role in chemoprevention...
  90. ncbi Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation
    Wendy A Woodward
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:336-44. 2003
    ..CONCLUSIONS: Postmastectomy radiation decreases LRR for patients with breast cancer, including those with Stage II breast cancer and one to three positive lymph nodes...
  91. ncbi Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy
    Wendy A Woodward
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:327-35. 2003
    ..The rate of second non-breast cancer malignancy was increased among patients treated with >10 cycles of cyclophosphamide-containing chemotherapy...
  92. ncbi Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection
    Filippo Montemurro
    Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 9:330-40. 2003
    ..01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control...
  93. ncbi A roundtable discussion of aromatase inhibitors as therapy for breast cancer
    D Craig Allred
    Baylor College of Medicine, Houston, Texas, USA
    Breast J 9:213-22. 2003
    ..Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease...
  94. ncbi Efficacy of anastrozole in male breast cancer
    Sharon H Giordano
    University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Am J Clin Oncol 25:235-7. 2002
    ..D. Anderson from 1990 to 1999 were reviewed. Five male patients with metastatic breast cancer who were treated at M. D. Anderson with anastrozole were identified. We now report on these five cases...
  95. ncbi Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Breast J 8:2-9. 2002
    ..The benefit was greater on patients with node-negative primary tumors. In patients with stage IV-NED disease, doxorubicin-based chemotherapy should be considered standard treatment after adequate local control is achieved...
  96. ncbi T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy
    Amit K Garg
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:138-45. 2004
    ..For most patients with clinical T1 or T2 disease and one to three positive lymph nodes, the 5-year risk for LRR was low, and the routine inclusion of postmastectomy radiotherapy does not appear to be justified...
  97. ncbi 'Chemobrain' in breast carcinoma?: a prologue
    Jeffrey S Wefel
    Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:466-75. 2004
    ....
  98. ncbi The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach
    Paolo Morandi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Cancer 101:1482-9. 2004
    ..Ongoing clinical trials should help to define the precise timing, duration, and sequencing of AI therapy, in addition to the long-term tolerability profile and potential differences between anastrozole, letrozole, and exemestane...
  99. ncbi Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:472-80. 2006
    ....
  100. ncbi Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial
    Luigi Cataliotti
    Clinica Chirurgica 1, University degli Studi di Firenze, Firenze, Italy
    Cancer 106:2095-103. 2006
    ..Anastrozole appears to be at least as effective as tamoxifen in this setting, and more effective than tamoxifen in certain clinically relevant subgroups. Cancer 2006. (c) 2006 American Cancer Society...
  101. ncbi Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
    Valentina Guarneri
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
    J Clin Oncol 24:1037-44. 2006
    ..36 times the risk of death. CONCLUSION: pCR is associated with better outcome regardless of HR status in breast cancer patients who receive PC...